Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CHAMPIONS ONCOLOGY, INC. (CSBR)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jan-31-23 | Oct-31-22 | Jul-31-22 | Apr-30-22 | Jan-31-22 | Oct-31-21 | Jul-31-21 | Apr-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Total revenues | 12.8 | 14.3 | 13.7 | 12.9 | 13.2 | 11.8 | 11.3 | 10.6 |
| Revenue growth | -3.2% | 21.2% | 22.1% | 21.9% | 22.0% | 16.5% | 17.9% | 20.8% |
| Cost of goods sold | 7.7 | 7.4 | 7.1 | 6.2 | 6.4 | 5.6 | 5.4 | 5.8 |
| Gross profit | 5.1 | 6.8 | 6.7 | 6.7 | 6.8 | 6.2 | 5.9 | 4.7 |
| Gross margin | 39.7% | 47.9% | 48.7% | 51.7% | 51.4% | 52.4% | 52.0% | 44.7% |
| Selling, general and administrative [+] | 4.3 | 4.2 | 4.1 | 4.4 | 3.8 | 3.6 | 3.7 | 3.3 |
| Sales and marketing | 1.8 | 1.7 | 1.7 | 1.6 | 1.5 | 1.6 | 1.6 | 1.5 |
| General and administrative | 2.6 | 2.5 | 2.4 | 2.8 | 2.2 | 2.0 | 2.2 | 1.8 |
| Research and development | 3.2 | 2.6 | 2.9 | 2.6 | 2.2 | 2.3 | 2.3 | 2.1 |
| EBITDA [+] | -3.5 | 0.6 | 0.2 | 0.3 | 1.2 | 0.6 | 0.1 | -0.3 |
| EBITDA growth | -389.1% | -6.9% | 71.8% | -174.5% | -4.1% | 93.9% | -52.8% | -76.2% |
| EBITDA margin | -27.7% | 4.0% | 1.8% | 2.0% | 9.3% | 5.2% | 1.3% | -3.3% |
| Depreciation and amortization | -1.1 | 0.6 | 0.5 | 0.6 | 0.4 | 0.3 | 0.3 | 0.3 |
| EBIT [+] | -2.5 | 0.0 | -0.3 | -0.3 | 0.8 | 0.3 | -0.2 | -0.6 |
| EBIT growth | -396.1% | -97.3% | 62.3% | -52.0% | -15.5% | 3657.1% | -829.2% | -61.8% |
| EBIT margin | -19.2% | 0.0% | -2.1% | -2.4% | 6.3% | 2.2% | -1.6% | -6.1% |
| Other income (expense), net [+] | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -2.4 | 0.0 | -0.3 | -0.3 | 0.8 | 0.3 | -0.2 | -0.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.6% | 1.4% | 4.2% | | |
| Net income | -2.4 | 0.0 | -0.3 | -0.3 | 0.8 | 0.3 | -0.2 | -0.7 |
| Net margin | -19.1% | -0.1% | -2.3% | -2.7% | 6.0% | 2.4% | -1.5% | -6.4% |
| |
| Basic EPS [+] | ($0.18) | $0.00 | ($0.02) | ($0.03) | $0.06 | $0.02 | ($0.01) | ($0.05) |
| Growth | -408.6% | -105.7% | 83.8% | -49.1% | -18.7% | 26848.5% | -317.8% | -72.0% |
| Diluted EPS [+] | ($0.18) | $0.00 | ($0.02) | ($0.02) | $0.05 | $0.02 | ($0.01) | ($0.05) |
| Growth | -428.8% | -106.2% | 83.8% | -47.4% | -17.3% | 28576.6% | -343.5% | -74.7% |
| |
| Shares outstanding (basic) [+] | 13.6 | 13.5 | 13.5 | 13.2 | 13.5 | 13.4 | 13.4 | 13.1 |
| Growth | 0.4% | 0.7% | 0.9% | 0.4% | 1.0% | 2.8% | 5.3% | 10.9% |
| Shares outstanding (diluted) [+] | 13.6 | 13.5 | 13.5 | 14.2 | 14.4 | 14.5 | 13.4 | 14.6 |
| Growth | -5.8% | -7.0% | 0.9% | -2.8% | -0.8% | -3.4% | -5.8% | 23.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|